Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

ABSTRACT: The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer

DISEASE(S): Metastatic Colorectal Cancer,Second-line Treatment For Metastatic Colorectal Cancer,Colorectal Cancer (crc),Colorectal Neoplasms

PROVIDER: 2068498 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR